Shanghai Medicilon Inc.’s Net Profit Rose 18.8% in 2022

Shanghai Medicilon Inc. (上海美迪西生物医药股份有限公司) (688202.SH) reported a net profit of 338.2 million yuan in 2022, up 18.8% year-on-year.

Meanwhile, the company posted 1.7 billion yuan in revenue, up 42.1% year-on-year.

At the end of the reporting period, it had 2.3 billion yuan in total assets and 726.8 million yuan in total liabilities, with a liability-to-asset ratio of 31.2%.